Radiopharm Theranostics Limited (RADX) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

Radiopharm Theranostics Limited (RADX)

View Full Profile →

Intrinsic Value

DCF Not Suitable for RADX

Market cap ($0.04B) below $1B threshold — DCF not reliable for small-cap/micro-cap stocks.

Alternative Approach:

Use relative valuation (P/E, P/S) vs. peer group.

Frequently Asked Questions

Is RADX stock undervalued or overvalued?

Insufficient data to compute DCF valuation for RADX. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is RADX's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is RADX's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For RADX, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.